一种针对前蛋白转化酶枯草溶菌素9（PCSK9）的单克隆抗体对低密度脂蛋白胆固醇的影响。 - Suppr

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

作者信息

Milazzo Laura, Antinori Spinello

出版信息

N Engl J Med. 2012 Jun 21;366(25):2425; author reply 2426. doi: 10.1056/NEJMc1204929.

DOI:10.1056/NEJMc1204929

PMID:22716983

Abstract

摘要

相似文献

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

N Engl J Med. 2012 Jun 21;366(25):2425; author reply 2426. doi: 10.1056/NEJMc1204929.

[Effect of a monoclonal antibody to PCSK9 on LDL cholesterol].

Rev Clin Esp. 2012 Jul;212(7):408-9.

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

N Engl J Med. 2012 Jun 21;366(25):2425-6; author reply 2426. doi: 10.1056/NEJMc1204929.

Lowering plasma cholesterol by raising LDL receptors--revisited.

N Engl J Med. 2012 Mar 22;366(12):1154-5. doi: 10.1056/NEJMe1202168.

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

N Engl J Med. 2012 Mar 22;366(12):1108-18. doi: 10.1056/NEJMoa1105803.

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

JAMA. 2012 Dec 19;308(23):2497-506. doi: 10.1001/jama.2012.25790.

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

J Am Coll Cardiol. 2012 Jun 19;59(25):2344-53. doi: 10.1016/j.jacc.2012.03.007. Epub 2012 Mar 28.

PCSK9 inhibition: the next statin?

J Am Coll Cardiol. 2012 Jun 19;59(25):2354-5. doi: 10.1016/j.jacc.2012.03.011. Epub 2012 Mar 31.

Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.

N Engl J Med. 2015 Oct 22;373(17):1588-91. doi: 10.1056/NEJMp1508120. Epub 2015 Oct 7.

[PCSK9 inhibitors: new treatment to lower cholesterol].

Rev Med Suisse. 2016 Mar 2;12(508):440-2, 444.

引用本文的文献

PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?

Rev Cardiovasc Med. 2022 Nov 9;23(11):380. doi: 10.31083/j.rcm2311380. eCollection 2022 Nov.

PCSK9 Inhibitors and Infection-Related Adverse Events: A Pharmacovigilance Study Using the World Health Organization VigiBase.

Drugs Real World Outcomes. 2024 Sep;11(3):465-475. doi: 10.1007/s40801-024-00430-5. Epub 2024 Jul 2.

Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.

PLoS One. 2016 Apr 26;11(4):e0154498. doi: 10.1371/journal.pone.0154498. eCollection 2016.

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.

Lancet. 2014 Jan 4;383(9911):60-68. doi: 10.1016/S0140-6736(13)61914-5. Epub 2013 Oct 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献